PSA screening in men over 70 remains outside routine guidance
For men older than 70, prostate cancer screening sits in a difficult place between biology and bedside judgment. The US Preventive Services Task Force recommends against routine PSA screening in this age group because prostate cancer often grows slowly, and many older men are more likely to die with the disease than from it. In that setting, the harms of finding and treating PSA-detected cancer can outweigh the benefit of earlier detection.
Yet screening still happens in practice, and not always by design. A man may request testing after urinary symptoms appear, or a physician may order a PSA test during evaluation of fatigue, bone pain, or trouble urinating. Once symptoms are present, the conversation changes from prevention to diagnosis of potentially advanced disease. In older men, that often means metastatic prostate cancer is found only after the cancer has already moved beyond the prostate.
The screening guidance itself is due for revision. The last USPSTF update was published in 2018, and life expectancy among men over 70 has continued to rise, making age alone a less complete way to think about who might benefit from testing and who should be spared from it.
Biopsy, digital rectal exam, and MRI define the next step
A positive PSA result does not establish cancer on its own. The usual next step is a prostate needle biopsy, paired with a digital rectal exam to feel for suspicious changes in the gland. A palpable nodule can raise concern even before pathology is available, and urinary symptoms may point to disease that is already clinically active.
MRI has taken on a bigger role in this workup. Rather than simply confirming that something is abnormal, prostate MRI helps localize areas that deserve more precise biopsy sampling. This matters because prostate cancer is not always uniform across the gland; a targeted biopsy can improve the chance of identifying the most aggressive portion of the tumor.
Grade groups and genetics separate indolent disease from dangerous disease
Once tissue is obtained, pathology becomes the map. The classic Gleason score still matters, but it now sits alongside a five-tier Grade Group system that is easier to interpret at the bedside. Grade Group 1 corresponds to the least dangerous tumors, while Grade Group 5 reflects the most aggressive disease. A Gleason score of 3+3=6 aligns with Grade Group 1; a score of 4+5=9 aligns with Grade Group 5.
This grading matters because metastatic spread is not random. Tumors with irregular cell shapes and sizes, faster division, and invasion into nearby tissue are more likely to escape the prostate and seed distant sites. Genetic information adds another layer. Men with inherited BRCA1 or BRCA2 mutations face higher risk for more aggressive prostate cancer, and those same mutations can affect relatives through associated cancer risk in the family.
Genetic testing is not only prognostic. It can also redirect treatment toward drugs that exploit specific DNA-repair vulnerabilities.
PSMA imaging has replaced older staging logic
For years, staging often relied on CT scans of the abdomen and pelvis plus a bone scan. Those tests still have a role, but they are increasingly dated for detecting small-volume spread. Current practice has shifted toward imaging that targets prostate-specific membrane antigen, or PSMA, a protein expressed at high levels on many prostate cancer cells.
PSMA imaging is more sensitive because it can identify tumors that remain too small to be seen on conventional scans. When metastatic disease is found, the burden of spread is often described as high-volume or low-volume. Men with no more than three to five metastases are considered to have oligometastatic prostate cancer, a category that can influence whether local radiation is added to systemic treatment.
Hormone therapy still anchors treatment, but combination therapy is now routine
Metastatic prostate cancer treatment rarely begins with a single drug. For low-volume disease, the standard approach is often doublet therapy: one medication suppresses testosterone production and another blocks testosterone from binding to its receptor. The testosterone-suppressing agent named here is leuprolide (Lupron). The other drugs are androgen receptor pathway inhibitors, or ARPIs, including enzalutamide (Xtandi), daralutamide (Nubeqa), apaludamide (Erleada), and abiraterone (Zytiga), which works through a slightly different mechanism.
The biology is straightforward even when the treatment choices are not. Prostate cancer depends on androgen signaling to grow, so cutting off that signal can slow or halt tumor expansion. When disease progresses despite doublet therapy, chemotherapy can be added, creating triplet therapy with leuprolide, an ARPI, and chemotherapy. In some men, immediate triplet therapy is chosen up front depending on the extent of spread.
A direct sentence applies here: metastatic disease no longer automatically means a short horizon.
PSMA-positive disease opens the door to radioligand therapy and focused radiation
Treatment options widen further when tumor biology and metastatic pattern align with newer technologies. Men with PSMA-positive disease may receive Lutetium-177, an intravenously delivered radioligand that seeks out PSMA-expressing cells and destroys them with radioactive particles. This approach is designed to follow the molecular footprint of the cancer rather than simply blanket the body with treatment.
Men with oligometastatic disease may also be candidates for metastasis-directed therapy, or MTD, which uses highly focused external-beam radiation to treat metastatic deposits directly. In a limited number of lesions, local control can matter, especially when the total burden of disease is still relatively small.
BRCA mutations and microsatellite instability guide targeted therapy
Genetic findings can change the drug list in a concrete way. Men with BRCA1 or BRCA2 mutations may receive doublet therapy plus a PARP inhibitor. Two PARP inhibitors are approved for this setting: olaparib (Lynparza) and rucaparib (Rubraca). These drugs work by exploiting defects in DNA repair, a vulnerability that tumors with BRCA mutations carry from the start.
A different molecular abnormality, microsatellite instability, opens the way to pembrolizumab (Keytruda). The principle is the same: identify the tumor feature that drives growth and match it with a therapy that hits that feature directly.
Prognosis has improved, but cardiovascular risk cannot be ignored
The outlook for metastatic prostate cancer has changed substantially. Men once faced a far poorer prognosis, but survival of 10 years or longer is now common in some cases. Even the treatment philosophy has shifted. Radiation to the prostate itself is now being used more often in men with metastatic disease, even though that strategy was not part of older practice when spread beyond the gland was viewed as the point of no return.
Before hormonal therapy begins, a cardiac evaluation is advised. Hormonal treatment can worsen cardiovascular risk factors, and those issues need attention before and during cancer therapy. For older men in particular, prostate cancer management is no longer just a question of tumor control; it is also a question of whether the heart, vessels, and metabolic system can tolerate the treatment path chosen for the cancer.